Atreca to Participate at Cowen’s 43rd Annual Health Care Conference
01 mars 2023 08h00 HE
|
Atreca, Inc.
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
06 févr. 2023 08h00 HE
|
Atreca, Inc.
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics...
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
09 janv. 2023 08h30 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
10 nov. 2022 16h30 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused...
Atreca to Present at Upcoming Investor Conferences
07 nov. 2022 16h30 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
05 oct. 2022 16h05 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca to Present at Upcoming Investor Conferences
09 sept. 2022 16h05 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
08 août 2022 16h05 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca to Present at Upcoming Investor Conferences
02 août 2022 16h30 HE
|
Atreca, Inc.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
16 juin 2022 16h05 HE
|
Atreca, Inc.
SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique...